Analogies between atherosclerosis and age-related maculopathy: Expected roles of oxysterols;Analogies entre processus athéromateux et dégé nérescence maculaire liée à l'âge: Rôles présumés des oxystérols

Journal Francais d'Ophtalmologie

Volumn 29, Issue 5, 2006, Pages 570-578

  Malvitte, L ^a,b,c   Montange, T ^a   Joffre, C ^b   Vejux, A ^a   Maiza C ^a   Bron, A ^a   Creuzot Garcher, C ^a   Lizard, G ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b CEMAGREF   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

Age related maculopathy; Atherosclerosis; Lipoproteins; Oxysterols; Retinal pigment epithelial cells

Indexed keywords

CHOLESTEROL; OXYSTEROL;

ATHEROSCLEROSIS; BRUCH MEMBRANE; CYTOTOXICITY; DRUSEN; HUMAN; IMMUNOREACTIVITY; INFLAMMATION; OXIDATIVE STRESS; PATHOGENESIS; PHOTORECEPTOR; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

EID: 33745015348     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(06)73815-3     Document Type: Article

References (70)

1. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten year incidence and progression of age related maculopathy: the Beaver Dam Eye study. Ophthalmology, 2002;109:1767-79.
2. Klein R, Klein BE, Linton KLP. Prevalence of age-related maculopathy. Ophthalmology, 1992;99:933-43.
3. Vingerling J, Dielemans I, Bots M, Hofman A, Grobbee D, de Jong P. Age-related macular degeneration is associated with atherosclerosis: the Rotterdam study. Am J Epidemiol, 1995;142:404-9.
4. Freidman E. The role of atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol, 2000;130:658-63.
5. Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res, 2001;20:227-53.
6. Klaver CCW, Kliffen M, van Duijn CM, Hofman A, Cruts M, Grobbee DE. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet, 1998;63:200-6.
7. Souied EH, Benlian P, Amouyel P, Feingold J, Lagarde JP, Munnich A et al. The ∈4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am J Ophthalmol, 1998;125:353-9.
8. Tomany SC, Wang JJ, Van Leeuwen R, Klein R, Mitchell P, Vingerling JR et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology, 2004;111:1280-7.
9. Van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci, 2003;44:3771-7.
10. Nowak M, Swietochowska E, Marek B, Szapska B, Wielkoszynski T, Kos-Kulda B et al. Changes in lipid metabolism in women with age-related macular degeneration. Clin Exp Med, 2005;4:183-7.
11. Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol, 2002;120:1357-63.
12. Vingerling JR, Hofman A, Grobbee DE, de Jong PTVM. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol, 1996;114:1193-6.
13. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 8. Arch Ophthalmol, 2001;119:1417-36.
14. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the committee on vascular lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355-74.
15. Carpenter KLH, Taylor SE, Van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ. Lipids and oxidized lipids in human atherosclerotic lesions at different stages of developpement. Biochim Biophy Acta, 1995;1256:141-50.
16. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med, 1999;340:115-26.
17. Davies MJ. Stability and unstability: tow faces of coronary atherosclerosis. Circulation, 1996; 94:2013-20.
18. Kliffen M, Van Der Schaft T, Mooy C, de Jong P. Morphologic changes in age-related maculopathy. Microsc Res Tech, 1997;36:106-11.
19. Arnold JJ, Quaranta M, Soubrane G, Sarks SH, Coscas G. Indocyanine green angiography of drusen. Am J Ophthalmol, 1997;124:344-56.
20. Chang AA, Morse LS, Handa JT, Morales RB, Tucker R, Hjelmeland L et al. Histologic localization of indocyanine green dye in aging primate and human ocular tissues with clinical angiographic correlation. Ophthalmology, 1998;105:1060-8.
21. Holz FG, Sheraidah G, Pauleikhoff D, Bird A. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane. Arch Ophthalmol, 1994;112:402-8.
22. Curcio C, Millican C, Bailey T, Kruth H. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci, 2001;42:265-72.
23. Reblin T, Meyer N, Labeur C, Henne-Bruns D, Beisiegel U. Extraction of lipoprotein(a), ApoB and ApoE from fresh human arterial wall and atherosclertic plaques. Atherosclerosis, 1995;113:179-88.
24. Niculescu F, Rus H, Porutiu D, Ghiurca V, Vlaicu R. Immunoelectron- microscopic localization of S-protein/vitronectin in human atherosclerotic wall. Atherosclerosis, 1989;78:197-203.
25. Mullins R, Russell S, Anderson D, Hageman G. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J, 2000;14:835-46.
26. Malek G, Li CM, Guidry C, Meideros NE, Curcio NE. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol, 2003;162:413-25.
27. Kroon PA. Cholesterol and atherosclerosis. Aust NZ J Med, 1997;27:492-6.
28. Mügge A. The role of reactive oxygen species in atherosclerosis. Z Kardiol, 1998;87:851-64.
29. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxydative stress in the pathogenesis of age-relatedmacular degeneration. Surv Ophthalmol, 2000;45:115-34.
30. Esterbauer H, Schaur RJ, Zollner H. Chemistery and biochemistery of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med, 1991;11:81-128.
31. Meagher EA, Fitzgerald GA. Indices of lipid peroxydation in vivo: strenghts and limitations. Free Radic Biol Med, 2000;28:1745-50.
32. Harman D. Lipofuscin and ceroid formation: the cellular recycling system. In: EA Porta editors. Lipofuscin and Ceroid Pigments. New York: Plennum Press; 1990. p. 3-15.
33. Schutt F, Bergmann M, Holz FG, Kopitz J. Proteins modified by malondialdheyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Invest Ophthalmol Vis Sci, 2003;44: 3663-8.
34. Kopitz J, Holz FG, Kaemmerer E, Schutt F. Lipids ans lipid peroxidation products in the pathogenesis of age-related macular degeneration. Biochimie, 2004;86: 825-31.
35. Terman A, Brunk UT. Ceroid/lipofuscin formation in cultured human fibroblasts: the role of oxidative stress and lysosomal proteolysis. Mech Ageing Dev, 1998;104:277-91.
36. Shimasaki H, Maeba R, Tachibana R, Ueta N. Lipid peroxydation and ceroid accumulation in macrophages cultured with oxidized low density lipoprptein. Gerontology, 1995;41:39-41.
37. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA, 2001;285:2481-5.
38. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA, 2004;291:704-10.
39. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P et al. Complement factor H variant increases the risk of age-related macular degeneration. Science, 2005308:419-21.
40. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukine-6, and other cardiovascular biomarkers. Arch Ophthalmol, 2005;123:774-82.
41. Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, Kuziel WA et al. An animal model of age-related macular degeneration in senescent Ccl-2 or Ccr-2 deficient mice. Nature Medecine, 2003;9:1390-7.
42. Fukuoka Y, Strainic M, Medof ME. Differential cytokine expression of human retinal pigment epithelial cells in response to stimulation by C5a. Clin Exp Immunol, 2003;131:248-53.
43. Oh H, Takagi H, Takagi C, Suzuma K, Otani A, Ishida K et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci, 1999;40:1891-8.
44. Holtkamp GM, Van Rossen M, De Vos AF, Willekens B, Peek R, Kijlstra A. Polarized secretion of IL-6 and Il-8 by human retinal pigment epithelial cells. Clin Exp Immunol, 1998;112:34-43.
45. Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med, 2004;14:161-5.
46. Mullins R, Anderson D, Russell S, Hageman G. Dendritic cells and proteins associated with immune-mediated processes are associated with drusen and may play a central role in drusen biogenesis. Invest Ophthalmol Visual Sci, 2000b;41(Suppl):S24.
47. Gerszten RE, Lim YC, Ding HT, Snapp K, Kansas G, Dichek DA et al. Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells: implications for atherogenesis. Circ Res, 1998;82:871-8.
48. Devine L, Lightman SL, Greenwood J. Role of LFA-1, ICAM-1, VLA-4 and VCAM-1 in lymphocyte migration across retinal pigment epithalial monolayers in vitro. Immunology, 1996;88:456-62.
49. Yeh DC, BulaDV, Miller JW, Gragoudas ES, Arroyo JG. Expression of leukocyte adhesion molecules in human subfoveal choroidal neovascular membranes treated with and without photodynamic therapy. Invest Ophthalmol Vis Sci, 2004;45:2368-73.
50. Guardiola F, Dutta PC, Codony RC, Savage GP. Cholesterol and Phytosterol oxydation products: analysis, occurrence, and biological effects. AOCS Press, Champaign, Illinois, USA;2002.
51. Schroepfer GJ. Oxysterols: modulators of cholesterol metabolism and other processes. Physiological Reviews, 2000;80:361-554.
52. Hodis HN, Crawford DW, Sevanian A. Cholesterol feeding increases plasma and aortic tissue cholesterol oxide levels in parallel: further evidence role for the role of cholesterol oxidation in atherosclerosis. Artheriosclerosis, 1991;89:117-26.
53. Addis PB, Warner GJ. The potential health aspects of lipid oxidation products in food. In: Free radicals and food additives (Aruoma I, Halliwell B, eds). Taylor and Francis Ltd, London, 77-119.
54. Leonarduzzi G, Sottero B, Poli G. Oxidized products of cholesterol: dietary, and metabolic origin, and proatherosclerotic effects (review). J Nutr Biochem, 2002;13:700-10.
55. Zhou Q, Smith TL, Kummerow FA. Cytotoxicity of oxysterols on cultured smooth cells from human umbilical arteries. Proc Soc Exp Biol Med, 1993;202:75-80.
56. Colles SM, Maxson JM, Carlson SG, Chisolm GM. Oxidized LDL-induced injury and apoptosis in atheroslerosis. Potential roles for oxysterols. Trends Cardiovasc Med, 2001;1:131-8.
57. Panini SR, Sinenski MS. Mechanisms of oxystero-induced apoptosis. Curr Opin Lipidol, 2001;12:529-33.
58. Lizard G, Monier S, Cordelet C, Gesquière L, Deckert V, Gueldry S et al. Characterization and comparison of the mod of cell death, apoptosis versus necrosis, induced by 7β-hydroxycholesterol and 7- ketohydroxycholesterol in the cells of the vascular wall. Arterioscler Thromb Vasc Biol, 1999;19:1190-200.
59. Chang JY, Chavis JA, LiuL Z, Drew PD. Cholesterol oxides induce programmed cell-death in microglial cells. Biochem Biophys Res Commun, 1998;249:817-21.
60. Miguet-Alfonsi C, Prunet C, Monier S, Bessede G, Lemaire-Ewing S, Berthier A et al. Analysis of oxidative processes and of myelin figures formation before and after the loss of mitochondrial transmembrane potential during 7-betahydroxycholesterol and 7-ketocholesterol induced apoptosis: comparison with various pro-apoptotic chemicals. Biochem Pharmacol, 2002;64:527-41.
61. Liu Y, Hulten LM, Wiklund O. Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol, 1997;7:317-23.
62. Gordiyenko N, Campos M, Lee J, Fariss R, Sztein J, Rodriguez I. RPE cells internalize low-density lipoprotein (LDL) and oxidized LDL (oxLDL) in large quantities in vitro and in vivo. Invest Ophthalmol Vis Sci, 2004;45:2822-9.
63. Ryeom SW, Sparrow JR, Silverstein RL. CD36 participates in the phagocytosis of rod outer segments by retinal pigment epithelium. J Cell Sci, 1996;109:387-95.
64. Rodriguez I. R, Alam S, Wha Lee J. Cytotoxicity of oxidized low-density lipoprotein in cultured RPE cells is dependent on the formation of 7-ketocholesterol. Invest Ophthalmol Vis Sci, 2004;45: 2830-7.
65. Ong JM, Aoki AM, Seigel GM, Sacerio I, Castellon R, Nesburn AB et al. Oxysterol-induced toxicity in R28 and ARPE-19 cells. Neurochem Res, 2003;28:883-91.
66. Moreira E.F, Jaworski C, Li A, Rodriguez IR. Molecular and biochemical characterization of a novel oxysterolbinding protein (OSBP2) highly expressed in retina. J Biol Chem, 2001;276,18570-8.
67. Lehto M, Olkkonen VM. The OSBP-related proteins: a novel family involved in vesicle transport, cellular lipid metabolism, and cell signalling. Biochem Biophys Acta, 2003;1631:1-11.
68. Lagace TA, Byers DM, Cook HW, Ridway ND. Altered regulation of cholesterol and cholesteryl ester synthesis in Chinese-hamster ovary cells overexpressing the oxysteol-binding protein is dependent on the pleckstrin homology domain. Biochem J, 1997;326:205-13.
69. McGwin G, Xie A, Owsley C. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology, 2005;112:488-94.
70. Guymer RH, Chiu AW, Lim L, Baird PN. HMG CoA reductase inhibitors (Statins): Do they have a role in age-related macular degeneration. Surv Ophthalmol, 2005;50:194-206.